Compare NBTX & PSNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBTX | PSNY |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | France | Sweden |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2018 | 2021 |
| Metric | NBTX | PSNY |
|---|---|---|
| Price | $39.35 | $8.93 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 1 | 2 |
| Target Price | ★ $36.00 | $15.00 |
| AVG Volume (30 Days) | 153.6K | ★ 170.1K |
| Earning Date | 03-31-2026 | 04-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.17 | $31.06 |
| Revenue Next Year | N/A | $47.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.41 | $0.50 |
| 52 Week High | $57.14 | $23.75 |
| Indicator | NBTX | PSNY |
|---|---|---|
| Relative Strength Index (RSI) | 48.30 | 17.93 |
| Support Level | $36.98 | $0.56 |
| Resistance Level | $41.06 | $23.01 |
| Average True Range (ATR) | 2.95 | 0.83 |
| MACD | -0.29 | -0.23 |
| Stochastic Oscillator | 15.87 | 7.02 |
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.